GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » PharmX Technologies Ltd (ASX:PHX) » Definitions » Gross Profit

PharmX Technologies (ASX:PHX) Gross Profit : A$2.07 Mil (TTM As of Dec. 2023)


View and export this data going back to 1973. Start your Free Trial

What is PharmX Technologies Gross Profit?

PharmX Technologies's gross profit for the six months ended in Dec. 2023 was A$2.53 Mil. PharmX Technologies's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was A$2.07 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. PharmX Technologies's gross profit for the six months ended in Dec. 2023 was A$2.53 Mil. PharmX Technologies's Revenue for the six months ended in Dec. 2023 was A$3.14 Mil. Therefore, PharmX Technologies's Gross Margin % for the quarter that ended in Dec. 2023 was 80.59%.

PharmX Technologies had a gross margin of 80.59% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of PharmX Technologies was 89.49%. The lowest was 67.19%. And the median was 88.00%.

Warning Sign:

PharmX Technologies Ltd gross margin has been in long-term decline. The average rate of decline per year is -1.5%.


PharmX Technologies Gross Profit Historical Data

The historical data trend for PharmX Technologies's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmX Technologies Gross Profit Chart

PharmX Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.99 7.91 10.77 10.52 4.81

PharmX Technologies Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.26 5.26 5.27 -0.47 2.53

Competitive Comparison of PharmX Technologies's Gross Profit

For the Health Information Services subindustry, PharmX Technologies's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmX Technologies's Gross Profit Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's Gross Profit distribution charts can be found below:

* The bar in red indicates where PharmX Technologies's Gross Profit falls into.



PharmX Technologies Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

PharmX Technologies's Gross Profit for the fiscal year that ended in Jun. 2023 is calculated as

Gross Profit (A: Jun. 2023 )=Revenue - Cost of Goods Sold
=6.018 - 1.21
=4.81

PharmX Technologies's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=3.142 - 0.61
=2.53

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$2.07 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

PharmX Technologies's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=2.53 / 3.142
=80.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


PharmX Technologies  (ASX:PHX) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

PharmX Technologies had a gross margin of 80.59% for the quarter that ended in Dec. 2023 => Durable competitive advantage


PharmX Technologies Gross Profit Related Terms

Thank you for viewing the detailed overview of PharmX Technologies's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmX Technologies (ASX:PHX) Business Description

Traded in Other Exchanges
N/A
Address
17 Castlereagh Street, Level 11, Sydney, NSW, AUS, 2000
PharmX Technologies Ltd Formerly Corum Group Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business. the company discontinued the e-commerce business in 2022.